Camp4 Therapeutics (CAMP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Executive summary
Annual meeting scheduled for June 11, 2025, with voting available online or virtually until June 10, 2025.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of four Class I director nominees for three-year terms ending at the 2028 annual meeting.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Proxies may vote on other business arising at the meeting or any adjournment.
Board of directors and corporate governance
Nominees for Class I directors are James Boylan, Amir Nashat, ScD, Andrew J. Schwab, and Douglas Williams, PhD.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Camp4 Therapeutics
- Annual meeting to vote on director elections, auditor ratification, and equity plan amendment.CAMP
Proxy filing23 Apr 2026 - Key votes include director elections, auditor ratification, and an equity plan amendment.CAMP
Proxy filing23 Apr 2026 - First-in-class ASO therapy for SYNGAP1 epilepsy set for pediatric clinical trial this year.CAMP
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - Biotech IPO targets rare genetic diseases with RNA platform, but faces high risk and funding needs.CAMP
Registration filing1 Apr 2026 - IPO aims to fund RNA-based therapies for rare genetic diseases, but faces high financial risk.CAMP
Registration filing1 Apr 2026 - Biotech IPO seeks $66.7M to advance RNA therapeutics for rare genetic diseases.CAMP
Registration filing1 Apr 2026 - Annual meeting to elect directors, ratify auditor, and review governance, compensation, and ESG.CAMP
Proxy filing1 Apr 2026 - Signed exclusive GSK deal for ASO therapeutics: $17.5M upfront, up to $440M milestones, royalties.CAMP
Q4 20251 Apr 2026 - Biotech launches $100M at-the-market stock offering to fund R&D, with Leerink Partners as agent.CAMP
Registration filing1 Apr 2026